EVALUATE EFFECT OF INTRANASALLY ADMINISTERED INTERLEUKINS

评估鼻内给药白细胞介素的效果

• 批准号: 6264547
• 负责人: DAVID P SKONER
• 金额: $ 1.63万
• 依托单位: CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264547
• 关键词: clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; inhalation drug administration; interleukin 1; interleukin 10; interleukin 6; interleukin 8; outcomes research; respiratory disorder chemotherapy; respiratory disorder epidemiology; respiratory hypersensitivity; respiratory reflex; secretion; sign /symptom

To determine if topical, intranasal administration of Il-1B, Il-6, IL-8 or Il-10 alters nasal symptomatology and/or physiology. Non-allergic, asymptomatic allergic and symptomatic allergic subjects will be studied since these cytokines may produce differntial effects in these groups. Primary outcomes include nasal resistance, sneeze and cough counts, nasal secretion weights and nasal and throat symptom scores.

确定局部、鼻腔给药IL-1B、IL-6、IL-8或IL-10是否改变鼻部症状和/或生理。非过敏性、无症状过敏性和症状性过敏性受试者将被研究，因为这些细胞因子可能在这些群体中产生不同的影响。主要结果包括鼻腔阻力、打喷嚏和咳嗽次数、鼻分泌物重量以及鼻腔和喉咙症状评分。